Vogenx registers Phase 2b trial of mizagliflozin for post-bariatric hypoglycemia
The company listed a new placebo-controlled study testing mizagliflozin's ability to prevent low blood sugar episodes in patients with post-bariatric hypoglycemia.
Vogenx had one registry update this week, a new Phase 2b trial listing.
- Vogenx registered "EMERGE" (NCT07760961), a Phase 2b, randomized, placebo-controlled, double-blind study of mizagliflozin in patients with post-bariatric hypoglycemia. The trial is designed to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia1, with the study status listed as not yet recruiting. The study plans to enroll 36 participants across placebo, 5 mg, and 10 mg mizagliflozin arms, and its primary outcome is the number of combined Level 2 and Level 3 hypoglycemic events during the double-blind treatment period1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.